Posts

Posted on

iHeartMedia Completes Comprehensive Exchange Transactions

iHeartMedia Completes Comprehensive Exchange Transactions

NEW YORK–(BUSINESS WIRE)–
iHeartMedia, Inc. (NASDAQ: IHRT) (“iHeartMedia” or the “Company”) today announced the successful completion of its previously announced comprehensive exchange transactions of iHeartCommunications, Inc.’s (“iHeartCommunications”) outstanding 6.375% Senior Secured Notes due 2026 (the “2026 Secured Notes”), 5.25% Senior Secured Notes due 2027 (the “2027 Secured Notes”), 4.75% Senior Secured Notes due 2028 (the “2028 Secured Notes”), 8.375% Senior Notes due 2027 (the “Unsecured Notes”) and senior secured term loans due 2026 (the “Existing Term Loans”) (collectively, the “Existing Debt”) for new 9.125% Senior Secured First Lien Notes due 2029, 7.750% Senior Secured First Lien Notes due 2030, 7.000% Senior Secured First Lien Notes due 2031, 10.875% Senior Secured Second Lien Notes due 2030 and senior secured first lien term loans due 2029, respectively, in each case issued by iHeartCommunications (collectively, the “Exchange Offers”).

Approximately $4.8 billion (or 92.2%) of the aggregate principal amount of the Existing Debt participated in the Exchange Offers, which expired at 9:00 a.m., New York City time, on December 18, 2024 (the “Expiration Time”).

As a result of the transactions, iHeartMedia has extended the vast majority of its debt maturities by three years; its consolidated annual net cash interest payments are expected to remain relatively flat; and the Company has reduced its total debt by over $440 million. The completion of the Exchange Offers results in a strengthened capital structure that provides iHeartMedia with extended maturities which increases its flexibility to execute on its strategy and business initiatives.

As of the Expiration Time, approximately $755.4 million (or 94.4%) of the aggregate principal amount of the 2026 Secured Notes, approximately $743.0 million (or 99.1%) of the aggregate principal amount of the 2027 Secured Notes, approximately $223.1 million (or 44.6%) of the aggregate principal amount of the 2028 Secured Notes, approximately $844.0 million (or 92.1%) of the aggregate principal amount of the Unsecured Notes, in each case, were tendered in the Exchange Offers and approximately $2,258.7 million (or 99.7%) of the aggregate principal amount of the Existing Term Loans participated in the Exchange Offers.

Additional details on the completion of the comprehensive exchange transactions are included in a Form 8-K filed today.

Simpson Thacher & Bartlett LLP served as counsel and PJT Partners served as financial advisor to the Company. Davis Polk & Wardwell LLP served as counsel and Perella Weinberg Partners served as financial advisor to an ad hoc group of certain of the holders of the Existing Debt.

About iHeartMedia, Inc.

iHeartMedia, Inc. [Nasdaq: IHRT] is the leading audio media company in America, with 90% of Americans listening to iHeart broadcast radio in every month. iHeart’s broadcast radio assets alone have a larger audience in the U.S. than any other media outlet; twice the size of the next largest broadcast radio company; and over four times the ad-enabled audience of the largest digital only audio service. iHeart is the largest podcast publisher according to Podtrac, with more downloads than the next two podcast publishers combined, has the most recognizable live events across all genres of music, has the number one social footprint among audio players, with seven times more followers than the next audio media brand, and is the only fully integrated audio ad tech solution across broadcast, streaming and podcasts. The company continues to leverage its strong audience connection and unparalleled consumer reach to build new platforms, products and services. Visit iHeartMedia.com for more company information.

Media

Wendy Goldberg

Chief Communications Officer

(212) 377-1105

[email protected]

Investors

Mike McGuinness

EVP, Deputy CFO, and Head of Investor Relations

(212) 377-1336

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Entertainment Technology TV and Radio Mobile Entertainment Audio/Video Podcast

MEDIA:

Logo
Logo
Posted on

Digital Health Tools are Expanding in Scope and Function to Aid Patient Diagnosis, Treatment and Monitoring, Says New Report from The IQVIA Institute

Digital Health Tools are Expanding in Scope and Function to Aid Patient Diagnosis, Treatment and Monitoring, Says New Report from The IQVIA Institute

  • The number of digital health apps stands at 337,000, with disease-specific apps that bring more value to health systems growing in number and their focus expanding beyond mental health and chronic diseases to encompass other conditions.

  • Approval and reimbursement of digital tools is accelerating as payers recognize clinical utility and cost savings; of the more than 360 software-based digital therapies commercially available, 140 prescription digital therapeutics (DTx) are approved for patient use at home and over 220 therapies are used within digital care or in clinics.

  • Sensor-based digital biomarkers that track patient health using wearables now monitor patients in care and research, and the first digital endpoints have been approved by regulators in the U.S. and Europe.

  • More than 103 digital diagnostics for disease assessment are now commercially available and used to evaluate disease risk, accelerate diagnosis and monitor patient health; many of these are enabled by artificial intelligence and machine learning (AI/ML).

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–
Despite a drop in venture funding for digital health companies over the last two-and-a-half years, digital health products and solutions are expanding in scope and function to aid patient diagnosis, treatment, and monitoring. More solutions are now focused on specific diseases, and their commercial appeal has grown as developers build solutions that bring value back to providers, are more easily integrated with health systems, and embrace innovation such as AI to personalize care and reduce provider workload. Product types have also expanded, with health assessment tools such as digital diagnostics, sensor-based digital measures, and remote patient monitoring solutions joining digital therapeutics and consumer health apps to offer value for personal health and clinical care. These findings are based on a new report from the IQVIA Institute for Human Data Science: Digital Health Trends 2024: Implications for Research and Patient Care.

There are currently 337,000 digital health apps along with more than 360 software-based digital therapies and 103 digital diagnostics commercially available. Simultaneously, the number of AI/ML enabled mobile and point-of-care devices is growing.

“The landscape of digital health has evolved over the past two years, yielding new products that are more commercially viable and meet the needs of stakeholders across a broadening set of uses,” said Murray Aitken, executive director, IQVIA Institute for Human Data Science. “Digital health tools now support both patients and providers as they move from diagnosis to treatment and disease monitoring, with their scope expanding as new health assessment tools such as digital diagnostics have joined more mature digital therapies, accelerating care and closing gaps to improve health outcomes. Ultimately, these solutions will better fit into existing care pathways and bring benefits to more segments of patients and health systems.”

A few key highlights of the report include:

  • Digital health apps: Among the 337,000 digital health apps currently available, disease-specific apps continue to grow in number. While many continue to support mental health and patients with diabetes and cardiovascular diseases, recently-launched apps also help those with visual impairments, auditory issues and dermatologic conditions. Since app stores first emerged in 2008, over 1 million digital health apps have been created. However, two-thirds of these are no longer marketed, reflecting a high level of churn as many developers failed to differentiate their apps, consumer/patient uptake is relatively slow and financial returns have been meager. Apps with stronger clinical evidence have seen higher rates of use and more rapid uptake, indicating it is a key driver of consumer adoption and commercial success, as increased stakeholder focus is placed on evidence generation.
  • Digital therapeutics: Approvals and adoption of DTx, which treat or alleviate disease by delivering a medical intervention, have proliferated as opportunities to gain regulatory approval and reimbursement grow; 140 have received approval in one or more countries and are intended for patient use at home and more than 220 software-based digital therapies are being used by providers within digital care programs or in their clinics, totaling more than 360 commercially-available digital therapies. The most progress has been seen in Germany, which has led the regulatory process and reimburses for 56 DTx, followed by the U.S. with 46 approved and the UK with 20. Along with behavioral approaches to treat mental health and chronic diseases such as diabetes and hypertension, recently approved DTx use biofeedback and virtual reality to reduce various types of pain, treat visual impairments, support respiratory and post-stroke neurological rehabilitation, and treat PTSD and phobias.
  • Sensor-based digital measures: Through the use of digital sensors and wearables, nuanced aspects of health and patient experience are becoming traceable and measurable in daily life. In patient care and in clinical development programs for innovative medicines, sensor-based measures, including digital biomarkers and clinical outcome assessments, are proving valuable to remotely monitor patients, demonstrate the effects of therapeutic interventions and track outcomes. Life sciences companies have invested in the creation and validation of new digital endpoints, with some even building molecule-to-market digital strategies that overlay their drug development programs. By offering higher quality of data capture, more consistent measurements and increased sensitivity than traditional methods, some digital endpoints have optimized clinical development, allowing trial sponsors to reduce clinical trial enrollment and further promise to reduce trial duration and the need for patients to travel to trial sites. The first sensor-based digital endpoints using wearables have also been formally approved for ongoing use in clinical trials by regulators in the U.S. and Europe.
  • Digital diagnostics: Software-based devices that process signals from sensors have rapidly opened new routes to assess disease risk, accelerate diagnosis, monitor patient health and assess patient prognosis; and at least 103 such digital diagnostics are now commercially available. Notably, these digital health assessment tools are bringing new options to screen undiagnosed patients for diseases and enable providers to monitor patients remotely. Conditions now detectable using these tools include autism and autism spectrum disorders, sleep apnea, atrial fibrillation, skin cancers, epilepsy and sepsis, among others.
  • Use of AI/ML: Many health assessment devices are enabled by AI/ML, and in the U.S., around 75 of these mobile and point-of-care tools have been approved by the FDA. This fits within a broader trend toward using AI to improve diagnostic equipment, and as of June 2024, 801 distinct AI/ML-enabled devices have received approval from the FDA.
  • Remote patient monitoring: Digitaltools such as wearables and symptom-tracking apps are being combined into broader clinical platform solutions for providers to monitor disease progression or response to therapy, detect recurrence and even predict future health changes to triage patients in greatest need of care. This has enabled the creation of hospital-at-home solutions that continuously detect and predict adverse events, thereby speeding patient discharge from hospital settings and improving quality of life for patients being treated with advanced therapies and medicines with higher risk profiles. Growth in this area has also spurred the creation of accelerated approval and reimbursement pathways for remote monitoring technologies.
  • The uptake of digital health technologies: While the overall uptake of digital health technologies is rising, over the past two years it has been relatively limited and less than required to sustain high levels of investment, leading to multiple exits and restructuring by developers. Stakeholders in the digital health ecosystem are working through the regulatory and reimbursement challenges to attain sustainable investment and scaling of use that will provide maximum benefits to patients and health systems. The long-term potential for technology-supported and AI/ML-driven digital health interventions remains high despite near-term challenges.

About the IQVIA Institute for Human Data Science

The IQVIA Institute for Human Data Science contributes to the advancement of human health globally through timely research, insightful analysis and scientific expertise applied to granular non-identified patient-level data.

Fulfilling an essential need within healthcare, the Institute delivers objective, relevant insights and research that accelerate understanding and innovation critical to sound decision making and improved human outcomes. With access to IQVIA’s institutional knowledge, advanced analytics, technology and unparalleled data, the Institute works in tandem with a broad set of healthcare stakeholders to drive a research agenda focused on Human Data Science, including government agencies, academic institutions, the life sciences industry, and payers. More information about the IQVIA Institute can be found at www.IQVIAInstitute.org.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI™, advanced analytics, the latest technologies and extensive domain expertise. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behavior and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

Kerri Joseph, IQVIA Investor Relations ([email protected])

+1.973.541.3558

Alissa Maupin, IQVIA Media Relations ([email protected])

+1.919.923.6785

KEYWORDS: North Carolina United States North America

INDUSTRY KEYWORDS: Mental Health Technology Medical Devices Science Fitness & Nutrition Cardiology Biotechnology Wearables/Mobile Technology Health Other Science Apps/Applications Research Software Biometrics Data Management Practice Management Artificial Intelligence

MEDIA:

Posted on

FibroBiologics Announces $25 Million Financing

HOUSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it has entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN LTD. (“Yorkville”), an investment fund managed by Yorkville Advisors Global, LP. The agreement allows FibroBiologics, subject to customary conditions, to sell up to $25 million in the aggregate of its common stock to Yorkville over the course of two years.

Yorkville agreed to advance to FibroBiologics the first $15 million available under the SEPA in three equal tranches to be evidenced by convertible promissory notes. The first tranche in the amount of $5 million was funded upon entry into the SEPA. Subject to the satisfaction of certain conditions, the second tranche of $5 million will fund after the filing of a registration statement covering the resale of the shares issuable to Yorkville under the promissory notes, and the third tranche of $5 million will fund following the effectiveness of the registration statement and receipt of shareholder approval in satisfaction of Nasdaq rules. FibroBiologics can sell an additional $10 million of its common stock to Yorkville, subject to Yorkville’s consent and other conditions, while the convertible promissory notes remain outstanding.

“The initial advances from this financing will allow us to complete our first-in-human trial for diabetic foot ulcers as well as IND-enabling studies for our psoriasis program,” said Pete O’Heeron, Founder & Chief Executive Officer of FibroBiologics. “We expect to further develop our human longevity, multiple sclerosis, and cancer indications by utilizing the remaining capital available under the SEPA.”

For more information, please visit FibroBiologics’ website or email FibroBiologics at: [email protected]. For more information on the SEPA, including important terms and conditions, please see FibroBiologics’ filings with the Securities and Exchange Commission, including its Current Reports on Form 8-K filed with the Securities and Exchange Commission from time to time.

This communication shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of the securities discussed herein, in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

Cautionary Statement Regarding Forward-Looking Statements

This communication contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the funding of the advances under the SEPA, FibroBiologics’ ability to sell additional shares under the SEPA, and FibroBiologics’ ability to complete clinical trials and IND-enabling studies and to develop its other programs and indications. These forward-looking statements are based on FibroBiologics’ management’s current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics’ management’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption “Risk Factors” and elsewhere in FibroBiologics’ annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC’s website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics’ liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to satisfy the conditions under the SEPA and related agreements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.

General Inquiries:

[email protected]

Investor Relations:

Nic Johnson
Russo Partners
(212) 845-4242
[email protected]

Media Contact:

Liz Phillips
Russo Partners
(347) 956-7697
[email protected]



Posted on

Rectitude Secures Initial Sales Contracts for Innovative New Energy Solutions, Entering the Multi-Billion-Dollar Green Energy Market in Southeast Asia

SINGAPORE, Dec. 23, 2024 (GLOBE NEWSWIRE) — Rectitude Holdings Ltd. (Nasdaq: RECT; the “Company” or “Rectitude”), a Singapore-based provider of safety equipment and related industrial products, today announced that it has secured its first sales contracts for its new product, the All-in-One Intelligence Micro-grid System (“AIMS”). These contracts are expected to generate approximately USD 1 million in revenue. With the launch of AIMS and Rectitude’s expansion into Thailand, the Company is well-positioned to further growth across Southeast Asia.

The achievement follows Rectitude’s recent announcement of a strategic supply relationship with Nanjing Starship Intelligent Storage Technology Co. to deliver innovative new energy solutions in Southeast Asia. The successful sale of AIMS and entering a new country represent a key step in the Company’s strategy to penetrate a forecasted multi-billion-dollar Southeast Asian new energy solutions market and further strengthen Rectitude’s strategic expansion across the region.

“We have been actively executing our strategy to enter the green energy market by offering our all-in-one energy storage solution, targeting industries such as construction, mining, and rural electrification,” said Jian Zhang, Chairman, Chief Executive Officer, and Executive Director at Rectitude. “The initial sale of our AIMS product underscores our ability to deliver high-value, adaptable energy storage solutions while driving revenue growth and increasing profit margins, showcasing our success in penetrating new markets and rapidly expanding our presence and product offerings.”

The AIMS is designed to provide scalable, flexible, and integrated energy storage and management solutions tailored to the specific needs of diverse industries. With a focus on innovation and sustainability, Rectitude continues to strengthen its position as a leading provider of safety equipment, related industrial products, and energy solutions in Southeast Asia.

About Rectitude

Founded in 1997 in Singapore, Rectitude is principally involved in the provision of safety equipment, encompassing essential items such as personal protective clothing, gloves, safety footwear, personal fall arrest systems, portable fire extinguishers and traffic products. The Company also offers auxiliary products such as industrial hardware tools and electrical hardware required for construction sites. Rectitude’s products and solutions are marketed to a wide array of distributor networks and end markets, both in Singapore and increasingly throughout the Southeast Asian region, including Brunei, Cambodia, Malaysia, Indonesia, and Vietnam.

For more information, please visit the Company’s website: https://ir.rectitude.com.sg


Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, but not limited to, the Company’s proposed Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, including the expectation that the Offering will be successfully completed. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the U.S. Securities and Exchange Commission.

For investor and media inquiries, please contact:

Rectitude
Investor Relations
Email: [email protected]

Jackson Lin
Lambert by LLYC
Phone: +1 (646) 717-4593
Email: [email protected]



Posted on

COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization

Company leveraging core competencies to develop and commercialize 

natural-based products to improve health and wellness

Streamlined efficiencies and cost cutting measures taken to refine operations and development pathway forward

New corporate presentation outlining key development areas to be available in January 2025

TORONTO, ONTARIO, Dec. 23, 2024 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today provided a corporate update and reiterated its pipeline prioritization.

“Over the course of the last several months following the merger, we have taken strategic and deliberate steps to evaluate and prioritize our combined pipeline of products and programs. Through this effort, we have thoroughly evaluated the potential of our assets and prioritized the areas that we believe are high-value opportunities, and we plan to move forward focusing our resources on advancing a pipeline of natural-based products leveraging our core technologies. We believe that this focus, spanning cosmeceuticals, nutraceuticals and pharmaceuticals, positions us with near and long-term life science growth drivers and the potential to become a global leader in natural-based products for health and wellness,” stated Gilles Gagnon, M.Sc., MBA, President and CEO of COSCIENS. “In addition, we have continued to make progress driving revenues and growing our active ingredients base business. We are looking to kick off 2025 with a clear line of sight towards execution of our business plan and believe we are well-positioned for a transformational year.”


Development Projects Update

Pharmaceuticals:

  • Avenanthramides Tablets (Avs) in Development as an Anti-Inflammatory: The Phase 1-2a clinical trial being conducted at the Montreal Heart Institute has fully completed the Phase 1 part of the study with 72 subjects tested. No significant side effects have been observed from ascending doses ranging from 30 mg to 960 mg. The Company expects the Phase 2a efficacy study will be initiated in Q1 2025, with expected completion in Q3 2025.

Cosmeceuticals:

  • Enriched Oat Flour with High Concentration of Avenanthramides: We have successfully produced and sold small batches for inclusion in cream formulations.
  • JuventeDC Product Line: New website, juventedc.com, was launched on December 19, 2024.

Nutraceuticals:

  • Yeast Beta Glucan (YBG) Powder – Immune Booster: Our YBG product has been successfully manufactured as part of our PGX scale up project in Edmonton, Alberta. Our YBG product is being finalized in capsule form with the goal to commercialize it as an immune booster in Q2 2025.
  • Oat Beta Glucan (OBG) Chewable Bar – Cholesterol Reduction: We have successfully developed a unique, standardized formulation for a healthy confection which includes a high concentration of OBG with daily dosage according to approved claims in 10 developed countries. The substantive claims include reduction of LDL cholesterol, supporting cardiovascular health reduction of Type 2 diabetes risks, source of fiber for the maintenance of general good health and support of a healthy digestive system. COSCIENS’ team anticipates the official commercial launch of its chewable bar OBG natural health product in Q1 2025, marking an important chapter in the Company’s journey toward promoting wellness while expanding its business model.

Macimorelin:

  • On August 27, 2024, the Company announced that the Phase 3 safety and efficacy study AEZS-130-P02 (the “DETECT-trial”) evaluating macimorelin for the diagnosis of Childhood Onset Growth Hormone Deficiency (“CGHD”) had failed to meet its primary endpoints according to the definitions in the study protocol. Based on the results of the study, we are prioritizing our pipeline moving forward and repositioning the Company as a pure play Life Science’s business offering natural-based products. Therefore, while maintaining the current commercial indication for the use of macimorelin for the diagnosis of Adult Growth Hormone Deficiency (“AGHD”), the Company has decided to not make any future investments in macimorelin for the diagnosis of CGHD. Consequently, in order to further ensure the streamlining of operations and reduce costs, the roles of some additional members of management have been terminated, including Dr. Nicola Ammer, Chief Medical Officer, which will be ending on March 31, 2025.

“On behalf of the entire Board and Company, we are grateful to the members of the team for their years of dedicated service. Nicola has been a long-standing, valued member of our team and provided years of expertise for the development of macimorelin (Macrilen®; Ghryvelin®), the first and only U.S. FDA and European Medicines Agency approved oral test indicated for the diagnosis of adult growth hormone deficiency. We are thankful to each member of our team and sincerely thank them for the key roles they played,” concluded Mr. Gagnon.

The Company plans to release a new corporate presentation outlining key development areas and upcoming milestones in January 2025.

About COSCIENS Biopharma Inc.

COSCIENS is a specialty biopharmaceutical company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products. Our technology includes proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources currently used in cosmeceutical products (i.e., oat beta glucan and avenanthramides which are found in leading skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals. Our consolidated portfolio also includes macimorelin (Macrilen®; Ghryvelin®), the first and only U.S. FDA and European Medicines Agency approved oral test indicated for the diagnosis of adult growth hormone deficiency (“AGHD”).

The Company is listed on the NASDAQ Capital Market and the Toronto Stock Exchange, and trades on both exchanges under the ticker symbol “CSCI”. For more information, please visit COSCIENS’ website at www.cosciensbio.com.

Forward-Looking Statements

Certain statements in this news release, referred to herein as “forward-looking statements”, constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended, and “forward-looking information” under the provisions of Canadian securities laws. All statements, other than statements of historical fact, that address circumstances, events, activities, or developments that could or may or will occur are forward-looking statements. When used in this news release, words such as “anticipate”, “assume”, “believe”, “could”, “expect”, “forecast”, “future”, “goal”, “guidance”, “intend”, “likely”, “may”, “would” or the negative or comparable terminology as well as terms usually used in the future and the conditional are generally intended to identify forward-looking statements, although not all forward-looking statements include such words. Forward-looking statements in this news release include, but are not limited to, statements relating to: our goals and expectations regarding our plans related to the development, manufacture or commercialization of our products, our plans to drive revenues from our products, our expectation we have the potential to become a global leader in natural-based products for health and wellness.

Forward-looking statements are necessarily based upon a number of factors and assumptions that, while considered reasonable by the Company as of the date of such statements, are inherently subject to significant business, economic, operational and other risks, uncertainties, contingencies and other factors, including those described below, which could cause actual results, performance or achievements of the combined Company to be materially different from results, performance or achievements expressed or implied by such forward-looking statements and, as such, undue reliance must not be placed on them.

Forward-looking statements involve known and unknown risks and uncertainties which include, among others: the combined Company’s present and future business strategies; operations and performance within expected ranges; anticipated future cash flows; local and global economic conditions and the environment in which the combined Company operates; anticipated capital and operating costs; uncertainty in our revenue generation from our marketed products, product development and related clinical trials and validation studies; results from our products under development may not be successful or may not support advancing the product; the failure of the DETECT-trial to achieve its primary endpoint in CGHD may impact the market for macimorelin (Macrilen®; Ghryvelin®) in AGHD and the existing relationships we have for that product; ability to raise capital and obtain financing to continue our currently planned operations; our now heavy dependence on sales by and revenue from our main distributor of our legacy Ceapro products and its customers, the continued availability of funds and resources to successfully commercialize our products; the ability to secure strategic partners for late stage development, marketing, and distribution of our products; our ability to enter into out-licensing, development, manufacturing, marketing and distribution agreements with other pharmaceutical companies and keep such agreements in effect; our ability to protect and enforce our patent portfolio and intellectual property; and our ability to continue to list our common shares on the NASDAQ Capital Market.

Investors should consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties, including those discussed in our Annual Report on Form 20-F and MD&A filed under the Company’s profile on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. We disclaim any obligation to update any such risks or uncertainties or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or applicable law.

No securities regulatory authority has either approved or disapproved of the contents of this news release. The Toronto Stock Exchange accepts no responsibility for the adequacy or accuracy of this news release.

Issuer:

Gilles R. Gagnon
President & CEO
+1 (780) 421-4555
E: [email protected]

Investor Contact:

Jenene Thomas
JTC Team
T (US): +1 (908) 824-0775
E: [email protected]



Posted on

Osisko Announces Acquisition of Additional Gibraltar Silver Stream Interest and Closing of the Dalgaranga Royalties Acquisition

MONTRÉAL, Dec. 23, 2024 (GLOBE NEWSWIRE) — Osisko Gold Royalties Ltd (“Osisko” or the “Company”) (OR: TSX & NYSE) is pleased to announce that it has completed an amendment to its silver stream (the “Silver Stream”) with respect to the Gibraltar copper mine (“Gibraltar”), located in British Columbia (“BC”), Canada, which is operated by a wholly-owned subsidiary of Taseko Mines Limited (“Taseko”).

Osisko and Taseko have amended the Silver Stream to increase Osisko’s attributable silver percentage by 12.5% to 100%. Further to this, Osisko and Taseko have also extended the step-down silver delivery threshold to 6,811,603 ounces delivered, accounting for Osisko’s additional silver ownership. In exchange for these amendments Osisko has paid an additional deposit amount of US$12.7 million to Taseko. These amendments were concluded further to the announcement by Taseko on March 25th, 2024 that it had entered into a definitive agreement to consolidate a 100% interest in Gibraltar by acquiring the remaining 12.5% interest from Dowa Metals & Mining Co., Ltd. and Furukawa Co., Ltd.

Separately, Osisko is pleased to announce the successful closing of its transaction to acquire a 1.8% gross revenue royalty (“GRR”) on the Dalgaranga Gold project (the “Dalgaranga Royalty” and the “Project”) operated by Spartan Resources Limited (“Spartan”) in Western Australia for US$44 million, as originally announced on September 30th, 2024. Osisko’s complementary transaction to acquire a 1.35% GRR (the “Exploration Royalty”) on additional regional exploration licenses in proximity to Dalgaranga for US$6 million has also closed.

Jason Attew, President and CEO of Osisko commented:

“We are very pleased to have worked in partnership with Taseko to once again increase our silver exposure associated with the Gibraltar mine in BC. Osisko’s shareholders will benefit from the increased silver stream from a producing mine thanks to a transaction that is consistent with our strategy of adding cash flow from long-life assets in Tier 1 mining jurisdictions.

“Moving to Dalgaranga, since we announced the agreement to acquire the Dalgaranga Royalty just over two months ago, our new partner Spartan has continued to deliver on key milestones, including: the receipt of all key approvals and permits required for underground mining and development; the discovery of a new high-grade gold zone called “Freak”; and the release of an updated Mineral Resource Estimate which demonstrated an impressive 68% increase in contained Indicated ounces, and which will serve as the basis for the upcoming Dalgaranga Feasibility Study. In addition, Spartan recently completed a A$220 million equity raise, which puts the management team in a strong position to accelerate Dalgaranga’s re-start over the next 24 months.”

Qualified Person

The scientific and technical content of this news release has been reviewed and approved by Guy Desharnais, Ph.D., P.Geo., Vice President, Project Evaluation at Osisko Gold Royalties Ltd, who is a “qualified person” as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”).

About Osisko Gold Royalties Ltd.

Osisko Gold Royalties Ltd is an intermediate precious metal royalty company which holds a North American focused portfolio of over 185 royalties, streams and precious metal offtakes, including 21 producing assets. Osisko’s portfolio is anchored by its cornerstone asset, a 5% net smelter return royalty on the Canadian Malartic Complex, one of Canada’s largest gold mines.

Osisko’s head office is located at 1100 Avenue des Canadiens-de-Montréal, Suite 300, Montréal, Québec, H3B 2S2.

For further information, please contact Osisko Gold Royalties Ltd:

Grant Moenting
Vice President, Capital Markets
Tel: (514) 940-0670 #116
Mobile: (365) 275-1954
Email: [email protected]		 Heather Taylor
Vice President, Sustainability & Communications
Tel: (514) 940-0670 #105
Email: [email protected]


CAUTIONARY


NOTE


REGARDING


FORWARD-LOOKING


STATEMENTS

Certain statements contained in this press release may be deemed “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking statements are statements other than statements of historical fact, that address, without limitation, future events, the development of the Dalgaranga project as planned, including the delivery of the Dalgaranga Feasibility Study and the timely re-starting of Dalgaranga, management’s expectations on the growth of its asset base and expected development on time and on budget of the projects and properties underlying Osisko’s interests. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential”, “scheduled” and similar expressions or variations (including negative variations), or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors, most of which are beyond the control of Osisko, and actual results may accordingly differ materially from those in forward-looking statements. Such risk factors include, without limitation, (i) with respect to properties in which Osisko holds a royalty, stream or other interest; risks related to: (a) the operators of the properties, (b) timely development, permitting, construction, commencement of production, ramp-up (including operating and technical challenges), (c) differences in rate and timing of production from resource estimates or production forecasts by operators, (d) differences in conversion rate from resources to reserves and ability to replace resources, (e) the unfavorable outcome of any challenges or litigation relating title, permit or license, (f) hazards and uncertainty associated with the business of exploring, development and mining including, but not limited to unusual or unexpected geological and metallurgical conditions, slope failures or cave-ins, flooding and other natural disasters or civil unrest or other uninsured risks, (ii) with respect to other external factors: (a) fluctuations in the prices of the commodities that drive royalties, streams, offtakes and investments held by Osisko, (b) fluctuations in the value of the Canadian dollar relative to the U.S. dollar, (c) regulatory changes by national and local governments, including permitting and licensing regimes and taxation policies, regulations and political or economic developments in any of the countries where properties in which Osisko holds a royalty, stream or other interest are located or through which they are held, (d) continued availability of capital and financing and general economic, market or business conditions, and (e) responses of relevant governments to infectious diseases outbreaks and the effectiveness of such response and the potential impact of such outbreaks on Osisko’s business, operations and financial condition; (iii) with respect to internal factors: (a) business opportunities that may or not become available to, or are pursued by Osisko, (b) the integration of acquired assets or (c) the determination of Osisko’s PFIC status (d) that financial information may be subject to year-end adjustments. The forward-looking statements contained in this press release are based upon assumptions management believes to be reasonable, including, without limitation: the absence of significant change in Osisko’s ongoing income and assets relating to determination of its PFIC status, and the absence of any other factors that could cause actions, events or results to differ from those anticipated, estimated or intended and, with respect to properties in which Osisko holds a royalty, stream or other interest, (i) the ongoing operation of the properties by the owners or operators of such properties in a manner consistent with past practice and with public disclosure (including forecast of production), (ii) the accuracy of public statements and disclosures made by the owners or operators of such underlying properties (including expectations for the development of underlying properties that are not yet in production), (iii) no adverse development in respect of any significant property, (iv) that statements and estimates relating to mineral reserves and resources by owners and operators are accurate and (v) the implementation of an adequate plan for integration of acquired assets.

For additional information on risks, uncertainties and assumptions, please refer to the most recent Annual Information Form of Osisko filed on SEDAR+ at

www.sedarplus.ca

and EDGAR at

www.sec.gov

which also provides additional general assumptions in connection with these statements. Osisko cautions that the foregoing list of risk and uncertainties is not exhaustive. Investors and others should carefully consider the above factors as well as the uncertainties they represent and the risk they entail. Osisko believes that the assumptions reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be accurate as actual results and prospective events could materially differ from those anticipated such the forward-looking statements and such forward-looking statements included in this press release are not guarantee of future performance and should not be unduly relied upon.

In this press release, Osisko relies on information publicly disclosed by Taseko pertaining to the Gibraltar mine and the operation thereof and, therefore, assumes no liability for such third party public disclosure.

These statements speak only as of the date of this press release. Osisko undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by applicable law.



Posted on

Trane Technologies Named to S&P Dow Jones Sustainability World and North America Indices

Trane Technologies Named to S&P Dow Jones Sustainability World and North America Indices

SWORDS, Ireland–(BUSINESS WIRE)–
Trane Technologies (NYSE:TT), a global climate innovator, has been named to the S&P Dow Jones Sustainability World Index for the fourth consecutive year and the North America Index for the fourteenth consecutive year. The company performed in the 98th percentile in the Building Products industry in the S&P Global Corporate Sustainability Assessment (CSA score as of November 22, 2024), with a score of 100 in the Energy category, highlighting excellence in energy consumption and management programs.

“Inclusion in the S&P Dow Jones Sustainability Indices highlights our steadfast commitment and leadership in driving meaningful environmental change,” said Dave Regnery, Chair and CEO of Trane Technologies. “This achievement is a testament to the hard work and dedication of our team members, who consistently strive to fulfill our purpose of boldly challenging what’s possible for a sustainable world.”

Trane Technologies’ inclusion in the S&P Dow Jones Sustainability Indices highlights the company’s leadership and impact in sustainability, as well as its strong financial performance.

In September, the company became the first in its industry to commit to a 40% reduction in embodied carbon by partnering with material suppliers and incorporating circular design criteria, addressing the significant carbon footprint of buildings. This commitment builds on Trane Technologies’ 2030 Sustainability Commitments, including the Gigaton Challenge, and its pledge to be net-zero by 2050. The company’s emissions reduction targets have been externally validated by the Science Based Targets Initiative (SBTi).

Renowned for its transparency, credibility and accountability, Trane Technologies has recently received several additional recognitions for its performance and culture. The company was named to The Wall Street Journal’s Management Top 250 ranking for the fourth consecutive year, honored in multiple categories of Extel’s 2024 All-America Executive Team and was included in TIME’s inaugural ranking of the World’s Best Companies for Sustainable Growth.

The Dow Jones Sustainability World Index represents the top 10% of the 2,500 largest companies in the S&P Global Broad Market Index (BMI) based on long-term economic, environmental and social criteria. The North America Index represents the top 20% of the 600 largest U.S. and Canadian companies in the S&P Global BMI. The S&P Global Corporate Sustainability Assessment (CSA) is an annual evaluation of companies’ sustainability practices, and its scores are used to determine which companies are included in the Dow Jones Sustainability Indices (DJSI).

About Trane Technologies

Trane Technologies is a global climate innovator. Through our strategic brands Trane® and Thermo King®, and our portfolio of environmentally responsible products and services, we bring efficient and sustainable climate solutions to buildings, homes and transportation. For more on Trane Technologies, visit www.tranetechnologies.com.

About S&P Dow Jones Indices

S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets. S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit: www.spglobal.com/spdji.

This news release includes “forward-looking statements” within the meaning of securities laws, which are statements that are not historical facts, including statements that relate to our earnings outlook, sustainability commitments and the impact of these commitments. These forward-looking statements are based on our current expectations and are subject to risks and uncertainties, which may cause actual results to differ materially from our current expectations. Factors that could cause such differences can be found in our Form 10-K for the year ended December 31, 2023, as well as our subsequent reports on Form 10-Q and other SEC filings. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect the Company. We assume no obligation to update these forward-looking statements.

Media Contact:

Travis Bullard

+1-919-802-2593

[email protected]

Investors Contact:

Zachary Nagle

+1-704-990-3913

[email protected]

KEYWORDS: North Carolina Europe Ireland United States North America

INDUSTRY KEYWORDS: HVAC Environment Manufacturing Sustainability Construction & Property Building Systems

MEDIA:

Logo
Logo
Posted on

TC Energy provides results of Series 1 and Series 2 conversion elections

CALGARY, Alberta, Dec. 23, 2024 (GLOBE NEWSWIRE) — News Release – TC Energy Corporation (TSX:TRP) (NYSE:TRP) (TC Energy or the Company) today announced that 42,200 of its 14,577,184 fixed rate Cumulative Redeemable First Preferred Shares, Series 1 (Series 1 Shares) have been elected for conversion on Dec. 31, 2024, on a one-for-one basis, into floating rate Cumulative Redeemable First Preferred Shares, Series 2 (Series 2 Shares); and 3,889,020 of its 7,422,816 Series 2 Shares have been elected for conversion, on a one-for-one basis, into Series 1 Shares.

As a result of the conversions, TC Energy will have 18,424,004 Series 1 Shares and 3,575,996 Series 2 Shares issued and outstanding. The Series 1 Shares and Series 2 Shares will continue to be listed on the Toronto Stock Exchange (TSX) under the symbols TRP.PR.A and TRP.PR.F, respectively.

The Series 1 Shares will pay on a quarterly basis for the five-year period beginning on Dec. 31, 2024, as and when declared by the Board of Directors of TC Energy, a fixed dividend at an annualized rate of 4.939 per cent.

The Series 2 Shares will pay a floating rate quarterly dividend for the five-year period beginning on Dec. 31, 2024, as and when declared by the Board of Directors of TC Energy. The dividend rate for the Series 2 Shares for the first quarterly floating rate period commencing Dec. 31, 2024 to but excluding Mar. 31, 2025 is 5.401 per cent and will be reset every quarter.

Holders of Series 1 Shares and Series 2 Shares will have the opportunity to convert their shares again on Dec. 31, 2029 and in every fifth year thereafter as long as the shares remain outstanding. For more information on the terms of, and risks associated with an investment in the Series 1 Shares and the Series 2 Shares, please see the prospectus supplement dated Sept. 22, 2009 which is available on sedarplus.ca or on our website.

About TC Energy

We’re a team of 6,500+ energy problem solvers connecting the world to the energy it needs. Our extensive network of natural gas infrastructure assets is one-of-a-kind. We seamlessly move, generate and store energy and deliver it to where it is needed most, to homes and businesses in North America and across the globe through LNG exports. Our natural gas assets are complemented by our strategic ownership and low-risk investments in power generation.

TC Energy’s common shares trade on the Toronto (TSX) and New York (NYSE) stock exchanges under the symbol TRP. To learn more, visit us at TCEnergy.com.

FORWARD-LOOKING INFORMATION

This release contains certain information that is forward-looking and is subject to important risks and uncertainties (such statements are usually accompanied by words such as “anticipate”, “expect”, “believe”, “may”, “will”, “should”, “estimate”, “intend” or other similar words). Forward-looking statements in this document are intended to provide TC Energy security holders and potential investors with information regarding TC Energy and its subsidiaries, including management’s assessment of TC Energy’s and its subsidiaries’ future plans and financial outlook. All forward-looking statements reflect TC Energy’s beliefs and assumptions based on information available at the time the statements were made and as such are not guarantees of future performance. As actual results could vary significantly from the forward-looking information, you should not put undue reliance on forward-looking information and should not use future-oriented information or financial outlooks for anything other than their intended purpose. We do not update our forward-looking information due to new information or future events, unless we are required to by law. For additional information on the assumptions made, and the risks and uncertainties which could cause actual results to differ from the anticipated results, refer to the most recent Quarterly Report to Shareholders and Annual Report filed under TC Energy’s profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission at www.sec.gov.

-30-

Media Inquiries:

Media Relations
[email protected]
403-920-7859 or 800-608-7859

Investor & Analyst Inquiries:

Gavin Wylie / Hunter Mau
[email protected]
403-920-7911 or 800-361-6522

PDF available: http://ml.globenewswire.com/Resource/Download/4311d849-2771-488f-9221-617500731acf



Posted on

FlexShopper Announces First Come First Serve Extension of Rights Offering

All subscriptions will be honored from today going forward on a first come first serve basis

BOCA RATON, Fla., Dec. 23, 2024 (GLOBE NEWSWIRE) — FlexShopper (Nasdaq: FPAY) (“FlexShopper” or the “Corporation”) announced today that it has extended the expiration date of its previously announced rights offering to ensure adequate time for holders of rights to make their first come first serve investment decision and for additional orders to be processed on a first come first serve basis. All other terms and conditions, including pricing, of the rights offering remain unchanged. A myriad of events, including the disruption in the equity markets resulting from macroeconomic factors, the overhang from the budget deadlines and delivery of documents to our Canadian shareholders as a result of the recently ended Canada postal strike, are contributing factors to the extension.

FlexShopper has extended the expiration of the rights offering to 5:00 pm ET on Friday, January 10, 2025 (the “Extended Expiration Time”). Only shareholders that exercise their initial units will receive Series A, B, and C rights to purchase FlexShopper’s common stock. The respective expiration dates will be extended accordingly for the Series A, B and C common stock purchase rights, which are 30, 60 and 90 days following the closing date of the subscription offering.

FlexShopper encourages its rights holders to contact their broker or financial advisor’s Corporate Actions Department immediately to participate in the rights offering. Rights offering information can be found at https://www.sec.gov and https://investors.flexshopper.com.

The rights offering allows FlexShopper’s stockholders of record as of December 2, 2024 to purchase up to 35,000,000 units. The rights offering was made through a dividend in the form of two non-transferable basic subscription rights for each share of common stock or common stock equivalent owned on the record date. Each right permits the holder to purchase one unit at a fixed subscription price of $1.70 per unit. Each unit consists of one share of common stock, as well as short-term Series A, B and C rights to purchase additional shares of common stock at varying discounted market-based prices.

The rights offering includes an over-subscription privilege, which entitles each rights holder that exercises all its basic subscription privileges in full the right to purchase additional units that remain unsubscribed at the Extended Expiration Time. The over-subscription privileges are subject to availability and a pro-rata allocation of shares among participants. All basic subscription rights and over-subscription privileges may be exercised during the subscription period through the Extended Expiration Time. If a rights holder does not exercise their subscription rights before the Extended Expiration Time, such rights will be deemed expired and void and will have no value.

If shares of common stock are held in the rights holder’s name, and subscription rights will not be exercised through a broker, dealer, custodian bank or other nominee (including any mobile investment platform), then the subscription certificate, all other required subscription documents and subscription payments should be sent by mail to Continental Stock Transfer, the Subscription Agent, at the address below, to be received before the Extended Expiration Time. Participants should refer to the instructions included with the subscription documents for complete information regarding completing and submitting the subscription documents.

By Hand or Overnight Courier or Regular Mail:

 Continental Stock Transfer & Trust Company
1 State Street, 30th Floor
New York, NY 10004
Attention: Corporate Actions – FlexShopper, Inc.

A copy of the prospectus and related materials were sent to holders of record on December 3, 2024. Additionally, a copy of the prospectus may be requested from, and questions relating to the rights offering may be directed to, the information agent for the rights offering, as follows:


Rights Offering Information Agent

MacKenzie Partners, Inc.
7 Penn Plaza, Suite 503
New York, NY 10001
Telephone at (212) 929-5500 (bankers and brokers) or (800) 322-2885 (all others)
[email protected]

FlexShopper has engaged Moody Capital Solutions, Inc. (“Moody Capital”) to act as dealer-manager for the rights offering. Moody Capital Solutions, Inc. invites any broker-dealers interested in participating in the rights offering to contact [email protected]. Moody Capital is offering a selected dealer fee of $0.051 per unit to registered broker-dealers (who do not manage accounts on a discretionary basis) in connection with the solicitation and exercise of the subscription rights and acceptance by the Corporation of such subscription. Moody Capital has a selected dealer agreement and W-9 that must be completed before such selected dealer can accept payment from Moody Capital. Moody Capital is also offering 3% to selected dealers on the solicitation and exercise of Series A, Series B and Series C rights.

The Corporation recommends that current shareholders consider notifying their broker or financial advisor about the rights offering to ensure their ability to participate in the rights offering.

The Company’s registration statement on Form S-1 was declared effective by the U.S. Securities and Exchange Commission on November 29, 2024. The prospectus relating to and describing the terms of the rights offering has been filed with the SEC on December 2, 2024, and is available on the SEC’s website at www.sec.gov. This announcement shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.


About FlexShopper

FlexShopper, Inc. is a leading national financial technology company that offers innovative payment options to consumers. FlexShopper provides a variety of flexible funding options for underserved consumers through its direct-to-consumer online marketplace at Flexshopper.com and in partnership with merchants both online and at brick-and-mortar locations. FlexShopper’s solutions are crafted to meet the needs of a wide range of consumer segments through lease-to-own and lending products.


Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 (the “Act”) provides a safe harbor for forward-looking statements made by or on behalf of the Corporation. The information contained in this press release may include, but are not limited to, statements about undertaking the rights offering, as well as, operating performance, trends, events that we expect or anticipate will occur in the future, statements about sales levels, restructuring, profitability and anticipated expenses and cash outflows. All statements in this document other than statements of historical fact are statements that are, or could be, deemed “forward-looking statements” within the meaning of the Act and words such as “may,” “intend,” “believe,” “expect,” “anticipate,” “estimate,” “project,” “forecast” and other terms of similar meaning that indicate future events and trends are also generally intended to identify forward-looking statements. Forward-looking statements speak only as of the date on which such statements are made, are not guarantees of future performance or expectations and involve risks and uncertainties. For the Corporation, these risks and uncertainties include, but are not limited to: our ability to obtain adequate financing to fund our business operations in the future; the failure to successfully manage and grow our FlexShopper.com e-commerce platform; our ability to maintain compliance with financial covenants under our credit agreement; our dependence on the success of our third-party retail partners and our continued relationships with them; our compliance with various federal, state and local laws and regulations, including those related to consumer protection; the failure to protect the integrity and security of customer and employee information; and those discussed more fully in documents filed with the SEC by the Corporation, particularly in Item 1A, Risk Factors, in Part I of the Corporation’s Annual Report on Form 10-K for the year ended December 31, 2023, and Part II of the Corporation’s subsequently filed Quarterly Reports on Form 10-Q. The Corporation cannot guarantee any future results, levels of activity, performance or achievements. In addition, there may be events in the future that the Corporation may not be able to predict accurately or control which may cause actual results to differ materially from expectations expressed or implied by forward-looking statements. Except as required by U.S. federal securities law, we assume no obligation, and disclaim any obligation, to update forward-looking statements whether as a result of new information, events or otherwise.


Contacts

For FlexShopper:

Investor Relations
[email protected]

Investor and Media Contact:

Andrew Berger, Managing Director
SM Berger & Company, Inc.
Tel: (216) 464-6400
[email protected]



Posted on

Aveanna to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

ATLANTA, Dec. 23, 2024 (GLOBE NEWSWIRE) — Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on January 15, 2025.

Management will present at 10:30 a.m. PST followed by 1×1 investor meetings on the same day, January 15, 2025. Interested investors and other parties may also listen to a simultaneous webcast of the presentation by logging onto the Investor Relations section of the Company’s website at https://ir.aveanna.com/. The online replay will be available for a limited time shortly following the call.

About
Aveanna
Healthcare

Aveanna Healthcare is headquartered in Atlanta, Georgia and has locations in 33 states providing a broad range of pediatric and adult healthcare services including nursing, rehabilitation services, occupational nursing in schools, therapy services, day treatment centers for medically fragile and chronically ill children and adults, home health and hospice services, as well as delivery of enteral nutrition and other products to patients. The Company also provides case management services in order to assist families and patients by coordinating the provision of services between insurers or other payers, physicians, hospitals, and other healthcare providers. In addition, the Company provides respite healthcare services, which are temporary care provider services provided in relief of the patient’s normal caregiver. The Company’s services are designed to provide a high quality, lower cost alternative to prolonged hospitalization. For more information, please visit www.aveanna.com.

Investor
Contact

Matt Buckhalter
Chief Financial Officer [email protected]